
Citi downgrades Novo Nordisk on slowing GLP-1 drug prescriptions, signaling stock downside.
Citi has reiterated a 'sell' rating on Novo Nordisk, citing a slowdown in new prescriptions for its key GLP-1 obesity drugs, except oral Wegovy. Data up to August 21, 2026, shows significant declines in Rybelsus prescriptions and negative growth for ...
